13836-62-9Relevant articles and documents
Steric and stereoelectronic control of the mode selectivity as a function of alkene structure in the reaction with dimethyl α-peroxy lactone: Cycloadducts and ene products versus epoxides
Adam, Waldemar,Blancafort, Lluis
, p. 4778 - 4787 (1996)
The oxidation of di-, tri-, and tetrasubstituted alkenes 2 by dimethyl α-peroxy lactone (1) affords the cycloaddition, ene, and epoxidation products 3-6. In the presence of methanol, additionally the trapping products 7 are obtained. The observed dichotomy in the product distribution requires two different paths for this reaction, namely a path via an open, stretched 1,6 dipole and another path for epoxidation. Both paths arise from an SN2 attack of the double bond of the alkene 2 on the peroxide bond of the α-peroxy lactone 1, the first unsymmetrical (end-on attack), leading to the 1,6 dipole A, and the second symmetrical (central attack) with respect to the approach of the double bond, leading to epoxidation. The 1,6 dipole is postulated to afford the cycloadducts, of which the thermodynamically favored diastereomers are obtained, and the ene products. In the epoxidation, the α-lactone released after oxygen transfer oligomerizes to the polyester 8 or in the presence of methanol is trapped as α-methoxy acid 9. The reaction is regioselective both with respect to the attacked oxygen atom of the α-peroxy lactone 1, as revealed by the trapping products 7, as well as with respect to the attacking carbon atom for unsymmetrical alkenes 2c,d, as displayed by the ene products 5 and 6. The former regioselectivity is dictated by the inherent polarization of the peroxide bond through the carbonyl group which makes the alkoxy oxygen the more electrophilic one toward nucleophilic attack, while for the latter the incipient positive charge of the open 1,6 dipole is better stabilized by the more substituted carbon atom of the end-on attacking unsymmetrical alkene. The preferred reaction mode has been found to be sensitive to the structure of the alkene and the difference in reactivity has been explained in terms of steric and stereoelectronic factors. Thus, for the sterically less hindered cis-di- and trisubstitued alkenes the path along the open 1,6 dipole is favored (stereoelectronic control), while the more sterically demanding trans-di- and tetrasubstituted alkenes react by the epoxidation mode (steric control).
A Modular Synthesis of Teraryl-Based α-Helix Mimetics, Part 5: A Complete Set of Pyridine Boronic Acid Pinacol Esters Featuring Side Chains of Proteinogenic Amino Acids
Breinbauer, Rolf,Grimm, Sebastian,Schreiner, Till,Trobe, Melanie,Vareka, Martin,W?lfl, Bernhard
supporting information, (2022/03/02)
Teraryl-based α-helix mimetics have proven to be useful compounds for the inhibition of protein-protein interactions (PPI). We have developed a modular and flexible approach for the synthesis of teraryl-based α-helix mimetics using pyridine containing boronic acid building blocks to increase the water solubility. Following our initial publication in which we have introduced the methodology in combination with sequential Pd-catalyzed cross-coupling for teraryl assembly, we can now report a complete set of pyridine based boronic acid building blocks decorated with side chains of all proteinogenic amino acids relevant for PPI (Ala, Arg, Asn, Asp, Cys, Gln, Glu, His, Ile, Leu, Lys, Met, Phe, Ser, Thr, Trp, Tyr, Val) to complement the core fragment set. For a representative set of teraryls we have studied the influence of the pyridine rings on the solubility of the assembled oligoarenes.
NAPHTHYRIDINES AS INHIBITORS OF HPK1
-
Paragraph 0843; 0844, (2018/10/21)
Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.
Reactivity of an iron-oxygen oxidant generated upon oxidative decarboxylation of biomimetic iron(II) α-hydroxy acid complexes
Paria, Sayantan,Chatterjee, Sayanti,Paine, Tapan Kanti
supporting information, p. 2810 - 2821 (2014/04/03)
Three biomimetic iron(II) α-hydroxy acid complexes, [(Tp Ph2)FeII(mandelate)(H2O)] (1), [(Tp Ph2)FeII(benzilate)] (2), and [(TpPh2)Fe II(HMP)] (3), together with two iron(II) α-methoxy acid complexes, [(TpPh2)FeII(MPA)] (4) and [(Tp Ph2)FeII(MMP)] (5) (where HMP = 2-hydroxy-2- methylpropanoate, MPA = 2-methoxy-2-phenylacetate, and MMP = 2-methoxy-2-methylpropanoate), of a facial tridentate ligand TpPh2 [where TpPh2 = hydrotris(3,5-diphenylpyrazole-1-yl)borate] were isolated and characterized to study the mechanism of dioxygen activation at the iron(II) centers. Single-crystal X-ray structural analyses of 1, 2, and 5 were performed to assess the binding mode of an α-hydroxy/methoxy acid anion to the iron(II) center. While the iron(II) α-methoxy acid complexes are unreactive toward dioxygen, the iron(II) α-hydroxy acid complexes undergo oxidative decarboxylation, implying the importance of the hydroxyl group in the activation of dioxygen. In the reaction with dioxygen, the iron(II) α-hydroxy acid complexes form iron(III) phenolate complexes of a modified ligand (TpPh2*), where the ortho position of one of the phenyl rings of TpPh2 gets hydroxylated. The iron(II) mandelate complex (1), upon decarboxylation of mandelate, affords a mixture of benzaldehyde (67%), benzoic acid (20%), and benzyl alcohol (10%). On the other hand, complexes 2 and 3 react with dioxygen to form benzophenone and acetone, respectively. The intramolecular ligand hydroxylation gets inhibited in the presence of external intercepting agents. Reactions of 1 and 2 with dioxygen in the presence of an excess amount of alkenes result in the formation of the corresponding cis-diols in good yield. The incorporation of both oxygen atoms of dioxygen into the diol products is confirmed by 18O-labeling studies. On the basis of reactivity and mechanistic studies, the generation of a nucleophilic iron-oxygen intermediate upon decarboxylation of the coordinated α-hydroxy acids is proposed as the active oxidant. The novel iron-oxygen intermediate oxidizes various substrates like sulfide, fluorene, toluene, ethylbenzene, and benzaldehyde. The oxidant oxidizes benzaldehyde to benzoic acid and also participates in the Cannizzaro reaction.
N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities
-
Paragraph 0245, (2014/09/29)
Described are compounds of Formula 1 which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.
N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities
-
Paragraph 0376, (2014/09/30)
Described are compounds of Formula I which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.
1,3-Diethynylallenes: Stable monomers, length-defined oligomers, asymmetric synthesis, and optical resolution
Ter Wiel, Matthijs K. J.,Odermatt, Severin,Schanen, Patrick,Seiler, Paul,Diederich, Francois
, p. 3449 - 3462 (2008/02/12)
A series of differently substituted 1,3-diethynylallenes (DEAs) have been synthesized, confirming that the previously introduced construction protocols tolerate a variety of functional groups. The new DEAs bear at least one polar group to facilitate enantiomer separations on chiral stationary phases and to allow further functionalization. They are thermally and environmentally stable compounds since bulky substituents next to the cumulene moiety suppress the tendency to undergo [2+2] cyclodimerization. A series of length-defined oligomers were obtained as mixtures of stereoisomers by oxidative coupling of a monomeric DEA under Glaser-Hay conditions. The electronic absorption data indicate a lack of extended π-electron conjugation across the oligomeric backbone due to the orthogonality of the allenic π-systems. Remarkably, even complex mixtures of stereoisomers only yield one single set of NMR signals, which underlines the low stereodifferentiation in acyclic allenoacetylenic structures. Optical resolution of DEAs represents an amazing challenge, and preliminary results on the analytical level are reported. Asymmetric synthesis by Pd-mediated SN2′-type cross-coupling of an alkyne to an optically pure bispropargylic precursor opens another promising route to optically active allenes with stereoselectivities currently reaching up to 78 % ee. Wiley-VCH Verlag GmbH & Co. KGaA, 2007.
1,3-THIAZOLE-5-CARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS
-
Page/Page column 42-43, (2008/06/13)
This invention relates to novel 1, 3- thiazole-5 -carboxamide compounds of formula (I), pharmaceutical compositions containing such compounds, and the use of those compounds or compositions as cancer chemotherapeutic agents.
2-AMINOARYLCARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS
-
Page/Page column 50-51, (2010/02/15)
A compound having the formula (1) in which the ring containing E is a phenyl, a pyridine, or a pyrimidine. In formula (1) the symbol A represents (see structures) wherein the group R4 represents halogen, CF3, or H, provided that the maximum number of CF3 groups on any A is 2, and the maximum number of hydrogens on A is 2 for the A groups which together with the carbon atoms to which they are attached form 6-membered rings, and the maximum number of hydrogens on A is 1 for the A group which together with the carbon atoms to which it is attached forms a 5-membered ring. Z represents N or CH when E forms a phenyl ring, and represents CH when E forms a pyridine or pyrimidine. The groups R1, R2 and R3 and the subscripts a, b, and d are as defined in the text and claims. Pharmaceutical compositions containing a compound of formula (1) and methods of treating cancer using compounds of formula (1) are also disclosed and claimed.
1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS
-
Page/Page column 47-48, (2010/11/25)
This invention relates to novel 1 -Methyl- lH-pyrazole-4-carboxamide compounds, pharmaceutical compositions containing such compounds, and the use of those compounds or compositions as cancer chemotherapeutic agents.
